Previous randomised placebo-controlled trials with low-to-medium doses of baclofen (30–60 mg) showed inconsistent results, but case studies suggested a dose-response effect and positive outcomes in patients on high doses of...
In the field of substance use prevention and treatment choosing the correct terminology can be tricky, especially if we want to avoid contributing to stigmatised perceptions of people battling with substance use disorders.
‘Abuse’, ‘abuser...
Especially due to its large sample size and incorporation into the CPS survey, the TUS provides a unique opportunity for tracking long-term trends in tobacco use, cessation attempts, and tobacco-related policies; evaluation of tobacco...
Although progress in science has driven advances in addiction medicine, this subject has not been adequately taught to medical trainees and physicians. As a result, there has been poor integration of evidence-based...
Second cell of the Drug Treatment Matrix explores key studies on the impact of the practitioner on reducing harms associated with illegal drug use, in which trust emerges as a fundamental ingredient. Reconceptualise needle exchanges as safe...
ABSTRACT
Europe has the highest alcohol consumption and alcohol-attributable disease burden in the world. In 2011, all 53 Member States of the WHO European Region endorsed the European action plan to reduce the harmful use of alcohol 2012...
The new National Alcohol Policy for Malawi has been in the making since 2008, a process originally initiated by a group of NGOs. On the 18th of August almost ten years later the Minister of Health, Atupele Muluzi, could launch the final...
The neurobiological mechanisms that underlie the resistance of drug cue associations to extinction in addiction remain unknown. Fear extinction critically depends on the ventromedial prefrontal cortex (VMPFC). Here, we tested if...
Background: In May 2016, along with the latest European Tobacco Products Directive (TPD), standardised packaging legislation was implemented in the UK. During the following 12-month transition period, both new and old types of...
Background: Multimorbidity, the co-existence of two or more (2+) long-term conditions in an individual, is common among problem drug abusers.
Objective: To delineate the patterns, multimorbidity prevalence, and disease severity...
